UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 52

Sortiert nach

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

The lancet oncology, 2015-11, Vol.16 (15), p.1473-1482

2015

Link zum Volltext

Verfügbarkeit prüfen

External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model

International journal of clinical oncology, 2019-05, Vol.24 (5), p.526-532

2019

Link zum Volltext

Verfügbarkeit prüfen

Succinate Dehydrogenase‐Deficient Renal Cancer Featuring Fructose‐1,6‐Biphosphatase Loss, Pyruvate Kinase M2 Overexpression, and SWI/SNF Chromatin Remodeling Complex Aberrations: A Rare Case Report

The oncologist (Dayton, Ohio), 2021-09, Vol.26 (9), p.e1652-e1655

2021

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence

Clinical genitourinary cancer, 2024-02, Vol.22 (1), p.84-97

2024

Link zum Volltext

Verfügbarkeit prüfen

Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program

Clinical genitourinary cancer, 2019-06, Vol.17 (3), p.e556-e564

2019

Link zum Volltext

Verfügbarkeit prüfen

Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis

Endokrynologia Polska, 2019-01, Vol.70 (4), p.313-317

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of Feature Discretization on Classification Performance of Explainable Scoring-Based Machine Learning Model

Computational Science – ICCS 2022, p.92-105

Link zum Volltext

Verfügbarkeit prüfen

Pharmacotherapy of patients with metastatic renal-cell carcinoma - algorithm vs. Polish reality: [Polish version: Leczenie farmakologiczne chorych na rozsianego raka nerki - algorytm a polskie realia p. 299]

Contemporary oncology (Poznań, Poland), 2011-10, Vol.15 (5), p.299

Zolnierek, Jakub

2011

Link zum Volltext

Verfügbarkeit prüfen

Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.155-155

2023

Link zum Volltext

Verfügbarkeit prüfen

KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer

Future oncology (London, England), 2023-12, Vol.19 (37), p.2445-2452

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

Journal of cancer research and clinical oncology, 2010-03, Vol.136 (3), p.371-378

2010

Link zum Volltext

Verfügbarkeit prüfen

First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.432-432

2022

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular Comorbidities for Prediction of Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib

Kidney & blood pressure research, 2012-01, Vol.35 (6), p.468-476

2012

Link zum Volltext

Verfügbarkeit prüfen

Sequential therapy in treatment of patients with metastatic renal cell carcinoma

Contemporary oncology (Poznań, Poland), 2009-07, Vol.13 (3), p.113

Zolnierek, Jakub

2009

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2021-03, Vol.384 (9), p.829-841

2021

Link zum Volltext

Verfügbarkeit prüfen

New therapeutic options in systemic treatment of advanced cutaneous melanoma

Expert opinion on investigational drugs, 2013-02, Vol.22 (2), p.181-190

2013

Link zum Volltext

Verfügbarkeit prüfen

Sorafenib in the treatment of metastatic renal cell cancer

Contemporary oncology (Poznań, Poland), 2008-11, Vol.12 (7), p.314

Zolnierek, Jakub

2008

Link zum Volltext

Verfügbarkeit prüfen

Hypertension as a Predictive Factor for Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib after Progression on Cytokines

Kidney & blood pressure research, 2012-01, Vol.35 (1), p.18-25

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.4506-4506

2015

Link zum Volltext

Verfügbarkeit prüfen

SDH- deficient renal cancer featured by the FBP1 loss, PKM2 overexpression and SWI/SNF chromatin remodeling complex aberrations: a rare case report

The oncologist (Dayton, Ohio), 2021-05

2021

Link zum Volltext

Verfügbarkeit prüfen

Okrągły stół 2013: zalecenia terapeutyczne w leczeniu systemowym rozsianego raka nerkowokomórkowego

Nowotwory, 2014-11, Vol.64 (5), p.443-453

2014

Link zum Volltext

Verfügbarkeit prüfen

SU 11248 as a novel agent for cancer treatment

Contemporary oncology (Poznań, Poland), 2005-03, Vol.9 (3), p.140

Zolnierek, Jakub

2005

Link zum Volltext

Verfügbarkeit prüfen

The first line therapy for intermediate/ high risk patients with advanced renal cell carcinoma according to therapeutic program B.10

OncoReview, 2023-08, Vol.13 (2(50)), p.48-57

Żołnierek, Jakub

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(51)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(26)
Oncology
(20)
Humans
(12)
Adult
(8)
Aged
(8)
Carcinoma, Renal Cell - Drug Therapy
(8)
Middle Aged
(8)
Female
(7)
Kidney Neoplasms - Drug Therapy
(7)
Male
(7)
Renal Cell Carcinoma
(6)
Treatment Outcome
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Urology & Nephrology
(5)
Metastasis
(4)
Retrospective Studies
(4)
Anilides - Adverse Effects
(3)
Antineoplastic Agents - Therapeutic Use
(3)
Cancer Research
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model

Succinate Dehydrogenase‐Deficient Renal Cancer Featuring Fructose‐1,6‐Biphosphatase Loss, Pyruvate Kinase M2 Overexpression, and SWI/SNF Chromatin Remodeling Complex Aberrations: A Rare Case Report

Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence

Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program

Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis

Effect of Feature Discretization on Classification Performance of Explainable Scoring-Based Machine Learning Model

Pharmacotherapy of patients with metastatic renal-cell carcinoma - algorithm vs. Polish reality: [Polish version: Leczenie farmakologiczne chorych na rozsianego raka nerki - algorytm a polskie realia p. 299]

Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial

Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort

KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer

Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study

Cardiovascular Comorbidities for Prediction of Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib

Sequential therapy in treatment of patients with metastatic renal cell carcinoma

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

New therapeutic options in systemic treatment of advanced cutaneous melanoma

Sorafenib in the treatment of metastatic renal cell cancer

Hypertension as a Predictive Factor for Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib after Progression on Cytokines

Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC)

SDH- deficient renal cancer featured by the FBP1 loss, PKM2 overexpression and SWI/SNF chromatin remodeling complex aberrations: a rare case report

Okrągły stół 2013: zalecenia terapeutyczne w leczeniu systemowym rozsianego raka nerkowokomórkowego

SU 11248 as a novel agent for cancer treatment

The first line therapy for intermediate/ high risk patients with advanced renal cell carcinoma according to therapeutic program B.10

Suchergebnisse filtern